<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398394</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00429</org_study_id>
    <nct_id>NCT04398394</nct_id>
  </id_info>
  <brief_title>Single Centre Study: Investigational Medical Device of Transscleral Optical Phase Imaging for Retinal Imaging in Healthy Eyes and Retinal Pathology.</brief_title>
  <acronym>ASSESS</acronym>
  <official_title>Fondation Asile Des Aveugles, Avenue de France 15, CH-1004 Lausanne, Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moser Christophe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eye Hospital Jules Gonin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ecole Polytechnique Fédérale de Lausanne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal diseases are the major cause of blindness in industrialized countries and while&#xD;
      tremendous effort is made to develop novel therapeutic strategies to rescue retinal cells,&#xD;
      optimal means to evaluate the effects of such treatments is still missing. Nowadays, diseases&#xD;
      diagnosis and treatment monitoring are performed thanks to imaging devices and functional&#xD;
      measurements (visual acuity of visual field tests). These eye examinations lead to the&#xD;
      detection of large scale damages of the retinal tissue, i.e. the diagnosis is made too late&#xD;
      or the treatments cannot be adapted in time. With the developed technology, the goal is to&#xD;
      provide a tool to the ophthalmologists that allow for better treatment monitoring and early&#xD;
      diagnosis. Indeed, the technology is able to image the retinal tissues with a ten times more&#xD;
      detailed visualization as compared to the standard of care (OCT instruments, SLO instruments&#xD;
      or eye fundus cameras). Towards this goal, we designed the present protocol in order to test&#xD;
      the technology with a clinical prototype (Cellularis version 1) in a clinical environment.&#xD;
      The objective is to describe and quantify at the cellular level the retina of patient&#xD;
      affected by different retinal diseases as well as the healthy retina of people with different&#xD;
      ages. We will assess the repeatability of the instrument and compare the results of the&#xD;
      measurements with images obtained with the standard of care (OCT and SLO images).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: 20 to 30 individuals with healthy retina, 18 to 50 years old. Group 2: 20 to 30 individuals with healthy retina and presenting with myopia, 18 to 50 years old.&#xD;
Group 3: 20 to 30 individuals with healthy retina, over the age of 50. Group 4: 25 to 50 patients with early and intermediate AMD, over the age of 50. Group 5: 25 to 50 patients with other retinopathies than AMD, over the age of 18.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number RPE [#/mm2]</measure>
    <time_frame>2 months</time_frame>
    <description>The primary outcome is the RPE cells density map of the imaged regions (in #/mm2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative analysis [unitless]</measure>
    <time_frame>2 months</time_frame>
    <description>Together with the quantitative outcomes of the density, a detailed qualitative analysis will also be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>averaged RPE cell area [um2]</measure>
    <time_frame>2 months</time_frame>
    <description>- The RPE cell area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Averaged number of neighbors of RPE cells [unitless]</measure>
    <time_frame>2 months</time_frame>
    <description>Averaged number of neighbors of RPE cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Averaged RPE spacing [um]</measure>
    <time_frame>2 months</time_frame>
    <description>The averaged RPE spacing in um.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Averaged RPE pigmentation parameter [unitless]</measure>
    <time_frame>2 months</time_frame>
    <description>RPE pigmentation parameter at cellular level</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Retinal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with healthy retina, 18 to 50 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with healthy retina and presenting with myopia, 18 to 50 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with healthy retina, over the age of 50.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with early and intermediate AMD, over the age of 50.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with other retinopathies than AMD, over the age of 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellularis version 1 imaging</intervention_name>
    <description>Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1&#xD;
&#xD;
          -  Individuals, 18 to 50 yo, with normal eye fundus.&#xD;
&#xD;
          -  Emmetropic or ametropic between +3D and -3D&#xD;
&#xD;
        Group 2&#xD;
&#xD;
          -  Individuals, 18 to 50 yo, with normal eye fundus.&#xD;
&#xD;
          -  Myopic between -6D and -12D.&#xD;
&#xD;
        Group 3&#xD;
&#xD;
          -  Individuals over the age of 50 and age-matched to patients with AMD.&#xD;
&#xD;
          -  With nwith normal eye fundus.&#xD;
&#xD;
          -  Astigmatic, myopic (&lt;-12D) or presbyopic participants may be included&#xD;
&#xD;
        Group 4&#xD;
&#xD;
          -  Patient over 50 yo, with early or intermediate AMD, including extrafoveolar geographic&#xD;
             atrophy&#xD;
&#xD;
          -  with visual acuity ≥ 0.6 and clinical judgment of good central fixation.&#xD;
&#xD;
        Group 5&#xD;
&#xD;
          -  Patient over 18, with other retinopathy than AMD,&#xD;
&#xD;
          -  with visual acuity ≥ 0.6 and nd clinical judgment of good fixation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Eye with&#xD;
&#xD;
          -  RPE detachment&#xD;
&#xD;
          -  a clinically unclear situation&#xD;
&#xD;
          -  abnormality preventing good visualization of the fundus&#xD;
&#xD;
          -  less than 3 months post-surgery of the anterior segment&#xD;
&#xD;
          -  less than 6 months post-surgery of the posterior segment&#xD;
&#xD;
          -  active uveitis - myopia ≥12D, hyperopia &gt; +5D, astigmatism &gt; 4D&#xD;
&#xD;
          -  contraindication to dilatation&#xD;
&#xD;
          -  a palpebral opening that is less than 6 mm in height&#xD;
&#xD;
        Individual:&#xD;
&#xD;
          -  albino - unable to fix a target at least 10 seconds&#xD;
&#xD;
          -  who does not tolerate being in the dark for 30 minutes&#xD;
&#xD;
          -  unable to follow the procedures of the study&#xD;
&#xD;
          -  refusing to be informed of the incidental discovery of a clinically significant&#xD;
             pathology Investigators of the study, their family members, collaborators and students&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Hospital Jules Gonin</name>
      <address>
        <city>Lausanne</city>
        <zip>1015</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irmela Mantel, MD</last_name>
      <phone>+41 21 626 8261</phone>
      <email>irmela.mantel@fa2.ch</email>
    </contact>
    <investigator>
      <last_name>Irmela Mantel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1038/s41566-020-0608-y</url>
    <description>Laforest, T., Künzi, M., Kowalczuk, L. et al. Transscleral optical phase imaging of the human retina. Nat. Photonics (2020).</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ecole Polytechnique Fédérale de Lausanne</investigator_affiliation>
    <investigator_full_name>Moser Christophe</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

